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Edited by Frances ShannonAbstract In order to investigate the epigenetic component of
Aiolos regulation, we analyzed the methylation status of its 5 0
CpG island in relation to histone modiﬁcations. Inhibition of
CpG methylation restores Aiolos expression, as well as euchro-
matin-associated markers, in U937 and 1106 mel cell lines.
DNA methylation and low levels of euchromatin-associated sig-
natures are observed in U937 and 1106 mel cell lines, while the
opposite characterizes Daudi, Jurkat, T and B cells. CpG meth-
ylation is not necessary to repress transcription in monocytes and
melanocytes where silencing mechanism involves heterochroma-
tin-associated signature. We show that DNA methylation directs
Aiolos silencing and chromatin status in tumor cell lines, while in
primary cells is mainly regulated by histone modiﬁcations.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A number of transcription factors have been shown to play a
critical role at speciﬁc stages of T and B cell diﬀerentiation [1].
Among these transcription regulators are the Ikaros family
nuclear proteins [2,3]. These proteins are essential for normal
lymphocyte development and appear to function as tumor sup-
pressors since their down-regulation in mice leads to leukemias
and lymphomas [4,5].
Aiolos is expressed in the late fetal thymus and in the adult
lymphoid organs. Within adult hemopoietic progenitors, Aio-
los is not expressed in pluripotent stem cells but is detected at
low levels in multipotent progenitors. Its expression is upregu-
lated as these progenitors become restricted into the T and B
lymphoid pathways [3]. The Aiolos transcription factor has
been reported to control T cell death by regulating the expres-
sion and localization of the anti-apoptotic molecule Bcl-2 [6],
raising the possibility that evasion of apoptotic cell death is
a common mechanism by which Ikaros family proteins partic-
ipate in leukemogenesis.
DNA and histone modiﬁcations participate in the establish-
ment of local chromatin structures that render gene promoter*Corresponding author. Fax: +33 142177490.
E-mail address: rebollo@chups.jussieu.fr (A. Rebollo).
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modiﬁcations of H3K4 di- and tri-methylation and H3K9
acetylation have been extensively associated with active re-
gions of the genome (euchromatin) while H3K9 and K27 tri-
methylation participate in the establishment and maintenance
of silent domains (heterochromatin) [8]. Tri-methylated H3K4
histones are associated with actives genes required for T cell
function [9]. Furthermore, it has been shown that Ikaros
expression in mouse pituitary cells is regulated through histone
modiﬁcations as well as DNA methylation [10]. In this manu-
script we have investigated the epigenetic component of Aiolos
regulation and show that Aiolos promoter methylation forms
the basis of its silencing in cancer cell lines, while its expression
in primary cells is mainly mediated by histone modiﬁcations.2. Materials and methods
2.1. Cell lines and culture
Daudi (human Burkitts lymphoma), Jurkat (human T lymphocyte
acute leukemia) andU937 (human hystiocytic lymphoma)were cultured
in RPMI supplemented with 10% heat-inactivated foetal calf serum and
2 mMglutamine. 1106mel (melanoma) cell line was cultured in DMEM
supplemented with 10% heat-inactivated foetal calf serum, 2 mM gluta-
mine, non-essential amino acids and 1 mM sodium pyruvate.
2.2. Isolation of haematopoietic and non-haematopoietic primary cells
Human melanocytes were obtained from skin samples of normal
adults undergoing plastic surgery or childrens foreskin obtained at cir-
cumcision. Monocytes, T and B cells were selected using positive selec-
tion. For ChIP experiments, monocytes, B and T cells were isolated
using Dynal negative isolation kits.
2.3. Treatment with chromatin-remodeling drugs and cloning of the
treated cell lines
Daudi, Jurkat and U937 cells, at a density of 0.5 · 106/ml were trea-
ted with 2 lM 5-Aza-2 0-deoxycitydine (5-Aza-dC) or 50 nM Trichosta-
tin A (TSA) every 48 h for diﬀerent periods of time. 1106 mel cells were
treated with 5 lM 5-Aza-dC or 300 nM TSA.
2.4. RT-PCR and RT-qPCR analysis
Total RNA extraction was done using Qiagen RNeasy kit. We syn-
thesized oligo(dT)-primed ﬁrst strand cDNA using Superscript II re-
verse transcriptase. Primer sequences are available upon request.
Quantitative PCR was carried out on an ABI PRISM 7300 detection
system. We used pre-developed TaqMan gene expression assays for
quantitative detection of human Aiolos (Hs00232635_m1) and the
absolute qPCR Rox mix. Data from triplicates are expressed as nor-
malized expression by using the 2DDCt calculation method and the
HPRT reference gene (Hs99999909_m1).blished by Elsevier B.V. All rights reserved.
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Genomic DNA was prepared using Qiagen DNeasy Kit. Samples
were treated with sodium bisulﬁte using MethylDetector bisulﬁte
modiﬁcation kit. Modiﬁed DNA was used for nested PCR ampliﬁca-
tion. The primer sequences are available upon request. PCR products
were gel-puriﬁed, cloned and transformed into TOP10 cells. Plasmid
DNA obtained was sequenced with BigDye terminator v3.1 cycle
sequencing kit.
2.6. Chromatin immunoprecipitation
ChIP assays were carried out as described [11]. The speciﬁc primer
set matches the CpG island, as well as upstream and downstream of
the CpG island. Sequences are available under request.
2.7. Western blot analysis
Wester blot were carried out as previously described [6].
2.8. In vitro methylation
A 370 pb fragment spanning the complete human Aiolos promoter
CpG island was obtained by PCR using genomic DNA from periphe-
ral blood mononuclear cells as template. The resulting fragment was
ﬁrst cloned into the pCRII-Topo vector and then transferred into
the pGL3-basic reporter vector, containing the luciferase reporter gene
[12]. Plasmid DNA was treated with S-adenosylmethionine and SssI
methylase. Complete methylation was veriﬁed by digestion with the
methylation-sensitive restriction enzyme HpaII.
2.9. Transient transfection and luciferase assay
Cells were transiently cotranfected with pGL3-370 Aiolos promoter
(methylated or not) and pRL-CMV vector, containing the renillase re-
porter gene. We used the following transfection methods: Jurkat and
U937 with cell line Nucleofactor V from Amaxa, Daudi with
DEAE-dextran and 1106 mel with JetPEI. After transfection
(24 h), cells were analyzed as previously described [12].Fig. 1. Aiolos gene CG proﬁl and expression in primary cells and cell lines.
island, including the exon 1 (rectangle) and the transcription initiation site (
shown. (B) Daudi; D, Jurkat; J, U937; U and 1106 mel; M cells were anal
antibody and PBGD were used as internal control. (C) Freshly isolated T and
expression.2.10. Statistical analysis
We used Prism4.0c (GraphPad Software, San Diego, CA) for statis-
tical analysis. Unpaired t tests with Welchs correction were realized
and statistical signiﬁcance was set at P < 0.05 with the following de-
grees: *0.01 < P 6 0.05, **0.001 < P 6 0.01, ***P < 0.001.3. Results
3.1. A CpG island ﬂanks the human Aiolos promoter
To characterize the molecular mechanisms of Aiolos tran-
scriptional regulation, we have isolated, sequenced and charac-
terized its promoter [12]. The main CpG island was detected
between 344 bp and the ATG codon. Fig. 1A shows the
GC percentage curve obtained with CpG islands in grey. We
analyzed Aiolos expression in diﬀerent cell lines and primary
cells. Daudi (B cell line) and Jurkat (T cell line) are positive
for Aiolos expression although the level of expression was
higher in Daudi cells. U937 (promonocyte) and 1106 mel (mel-
anoma) are negative for Aiolos expression (Fig. 1B). Freshly
isolated T and B cells are positive for Aiolos expression
(Fig. 1C). Monocytes show a background expression at the
mRNA level, but not at the protein level. Finally, melanocytes
are negative at both, mRNA and protein level (Fig. 1C).
3.2. Aiolos expression is increased in Aiolos positive and negative
cell lines after treatment with 5-Aza-deoxicytidine and/or
trichostatin
To clarify whether DNA methylation and histone acetyla-
tion are involved in transcriptional regulation of Aiolos, Dau-(A) The 5 0 ﬂanking region of the Aiolos gene contains a 342 bp CpG
arrow). The CG percentage curve obtained by Meth Primer analysis is
yzed for Aiolos expression at RNA and at protein level. Anti-histone
B cells, monocytes and melanocytes were analyzed as in (B) for Aiolos
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Aza-deoxicytidine (5-Aza-dC) and/or trichostatin (TSA).
Aiolos mRNA expression was up-regulated upon 24 h of treat-
ment of Daudi cells with 5-Aza-dC reaching the maximal level
of expression following 72 h of treatment (Fig. 2A). Similarly,
Aiolos expression was upregulated in 5-Aza-dC-treated Jurkat
cells after 24 h of treatment, reaching the highest level follow-
ing 144 h of treatment (Fig. 2A). Aiolos expression was in-
duced in U937 and 1106 mel cells upon 48 h of 5-Aza-dC
treatment (Fig. 2A). This result demonstrates that DNA meth-
ylation is suﬃcient to block Aiolos expression.Fig. 2. Analysis of Aiolos expression in cell lines treated with 5-Aza-dC and/
or treated with 2 lM of 5-Aza-dC or 50 nM of TSA. 1106 mel (M) cells were
as internal control. (B) Cells were treated for diﬀerent periods of time with 5-A
estimated by RT q-PCR. HPRT was used as internal control of q-PCR. D
compared to untreated ones.Similar results of Aiolos expression upregulation were ob-
tained upon treatment of Daudi and Jurkat cells with TSA
for 24 h (Fig. 2A). Treatment of 1106 mel with TSA induced
Aiolos expression upon 24 h, reaching the maximum level of
expression after 144 h of treatment (Fig. 2A). Finally, no Aio-
los expression was detected in U937 TSA-treated cells
(Fig. 2A).
After simultaneous treatment with 2 lM of 5-Aza-dC for
diﬀerent periods of time followed by 24 h treatment with
50 nM of TSA, Aiolos expression slightly increased in Daudi
cells, compared to non-treated cells. The same treatment ofor TSA. (A) Daudi (D), Jurkat (J) and U937 (U) were either untreated
treated with 5 lM 5-Aza-dC or 300 mM TSA. Kinase abelson was used
za-dC followed by 24 h treatment with TSA and Aiolos expression was
ata from triplicates are expressed as fold induction of treated cells
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compared to the individual treatment with these reagents. Sim-
ilar treatment of U937 cells showed a synergistic eﬀect of both
drugs, which increased as the incubation time is increased
(Fig. 2B). Finally, similar treatment of 1106 mel conﬁrmed
the importance of histone acetylation in Aiolos regulation. A
24 h treatment with TSA alone induced Aiolos mRNA expres-
sion compared to untreated cells. Longer treatment with
5-Aza-dC alone induced a moderate increase of Aiolos expres-
sion upon 72 h treatment (Fig. 2B). These results demonstrate
that inhibition of DNA methylation or histone deacetylation
restores Aiolos expression.
3.3. Demethylation of Aiolos promoter CpG island correlates
with Aiolos expression in cell lines but not in primary cells
We explored whether methylation patterns of the CpG rich
region of the Aiolos promoter are linked to Aiolos expression.
We examined the methylation status of the CpG island by
sodium bisulﬁte sequencing. The Aiolos promoter fragment
(306 to +36 bp) was treated with sodium bisulﬁte and ampli-
ﬁed by PCR. The PCR products were cloned and 10 clones
were sequenced. We observed that Daudi and Jurkat cells have
demethylated promoters in the ten analyzed clones and
demethylation correlates with Aiolos expression (Fig. 3A).Fig. 3. Methylation status of Aiolos in cell lines and primary cells. (A) Gen
cytosines to uracils. The Aiolos CpG island was then ampliﬁed by PCR, clone
pattern of ten clones is shown. Black circles; methylated cytosines, empty ciOn the contrary, Aiolos promoter is densely methylated
(98% and 71%, respectively) in U937 and 1106 mel cell lines
(Fig. 3A), which correlates with Aiolos silencing. This result
conﬁrms our hypothesis that methylation of the promoter re-
gion is associated with gene silencing since treatment of the
cells with 5-Aza-dC restored Aiolos gene expression.
We further analyzed whether there was also a correlation be-
tween CpG promoter methylation and Aiolos expression in
freshly isolated T, B, monocytes and melanocytes. Fig. 3B
shows that in B and T cells, the Aiolos promoter is densely
demethylated in eight and nine, respectively, out of the 10 ana-
lyzed clones showing a correlation between DNA demethyla-
tion and Aiolos expression. In monocytes and melanocytes,
the Aiolos promoter is also demethylated but cells do not ex-
press Aiolos (Fig. 3B).
U937 and 1106 mel cells, which do not express Aiolos, were
incubated for 8 days with 1 lM 5-Aza-dC and then cloned by
limiting dilution. This treatment induced Aiolos expression in
both cell lines as shown by PCR and Western blot (Fig. 4A).
Sequencing of bisulﬁte-treated DNA indicated that the 5 0-Aio-
los promoter has lower level of methylation upon 5-Aza-dC
treatment compared to the methylation level observed in
non-treated cells (Fig. 4B). 5-Aza-dC treatment strongly re-
duces the percentage of DNA methylation from 98% to 60%omic DNA was treated with sodium bisulﬁte to convert unmethylated
d and sequenced. For each cell line or primary cell (B), the methylation
rcles; unmethylated cytosines.
Fig. 4. Methylation status of Aiolos in cell lines treated with 5-Aza-dC. (A) Cell lines U937 and 1106 mel were treated with 1 lM 5-Aza-dC for eight
days and cloned by limiting dilution. Clones were analyzed for Aiolos expression by RT-PCR and Western blot. (B) U937 and 1106 mel were treated
as above and the methylation pattern of ten clones was analyzed using the sodium bisulﬁte DNA procedure. Black circles; methylated cytosines,
white circles; unmethylated cytosines. (C) T and B cells and monocytes were isolated from PBMC using positive selection and then treated with 5-
Aza-dC or TSA for eight days. Aiolos expression was analyzed by Western blot. Molecular weight of the protein is shown. NT, non-treated cells;
Aza, 5-Aza-dC treated cells; TSA, cells treated with TSA.
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sults show the inﬂuence of Aiolos CpG island methylation in
transcriptional silencing of Aiolos gene in cell lines. In parallel,
we analyze the contribution of 5-Aza-dC or TSA treatment to
the induction of Aiolos expression in primary cells (T, B and
monocytes). Results of Fig. 4C show that 5-Aza-dC treatment
does not modify Aiolos expression, in T and B cells compared
to non-treated cells. On the contrary, treatment of T and B
cells, as well as monocytes with TSA increases (T and B cells)
or induces (monocytes) Aiolos expression, suggesting that in
primary cells, Aiolos expression is mainly regulated by histone
modiﬁcations.
3.4. In vitro methylation of Aiolos promoter prevents its
transcriptional activity
To verify that CpG island methylation is able to modify Aio-
los promoter activity, a construct with a luciferase reporter
gene under the control of the Aiolos promoter was in vitro
methylated. The methylated and unmethylated constructs weretransfected in Daudi, Jurkat, U937 and 1106 mel cell lines, and
tested for luciferase activity. Fig. 5A shows the control using
HpaII methylation sensitive enzyme. Cells transfected with
the unmethylated construct displayed luciferase activity
(Fig. 5B). In contrast, those transfected with the methylated
construct showed no luciferase activity. This result conﬁrms
the role of CpG island methylation as part of the mechanism
that silences transcription.
3.5. Histone modiﬁcation patterns conﬁrm that Aiolos is silenced
by two distinct mechanisms in U937 and 1106 mel cells
To assess the role of histone modiﬁcation in the transcrip-
tional repression of Aiolos, as well as its relationship with
DNA methylation, we performed chromatin immunoprecipita-
tion (ChIP) assays. Fig. 6 shows that in the Daudi cell line, that
expresses Aiolos, with an unmethylated CpG island, the levels
of H3K4 di- and tri-methylated histones and the level of H3K9
acetylated histone are very high, showing a signiﬁcant increase
at 461 bp, followed by a decline around the CpG island. On
Fig. 5. Lack of Aiolos expression after in vitro methylation. (A) A
construct containing the CpG island (360 to +36 bp) of Aiolos
promoter fused to a luciferase reporter gene was methylated with SssI.
Methylation was veriﬁed by digestion with the methylation sensitive
restriction enzyme HpaII. (B) Daudi, Jurkat, U937 and 1106 mel cells
were transiently transfected with the above construct, either methyl-
ated or unmethylated. Transcription directed by the Aiolos promoter
was detected by measuring the luciferase activity and normalized to
renillase reporter gene activity. Statistical signiﬁcance was set at
p 6 0.05 with the following degrees: *0.01 < P 6 0.05, **0.001 <
P 6 0.01, ***P 6 0.001.
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and H3K27 tri-methylated histones remains insigniﬁcant.
In the Jurkat cell line, the histone modiﬁcation pattern is
bivalent. Indeed, the level of H3K4 di-methylated histone is
high, while the level of H3K4 tri-methylated and H3K9 acety-
lated H3 histone, is insigniﬁcant. The heterochromatin marker
tri-methylated H3K9 is negative, whereas tri-methylated
H3K27 is positive. The level of di-methylated H3K4 enrich-
ment is inferior to that reached by Daudi, which could explain
the diﬀerent Aiolos expression. In U937 and 1106 mel, the
euchromatin markers di and tri-methylated H3K4, as well as
acetylated H3K9, are negative or bearly detectable. The het-
erochromatin markers tri-methylated H3K9 and H3K27 are
enriched in 1106 mel cells principally in the CpG island region
and are low or very low in U937 cells.
To test whether CpG methylation is able to control histone
modiﬁcations, we treated U937 and 1106 mel cell lines with 5-
Aza-dC in order to demethylate the promoter. Once the
demethylation was conﬁrmed by bisulﬁte sequencing (Fig. 4),
we analyzed the status of histones. Demethylation of Aiolos
promoter in U937 and 1106 mell cell lines restored an euchro-
matin-associated signature, which corresponds to the pattern
of histone modiﬁcation of an Aiolos-expressing cell line
(Fig. 7). The heterochromatin markers were not modiﬁed (data
not shown). These results conﬁrm the existence of two diﬀerent
mechanisms for silencing Aiolos expression in myeloid U937
and the non-hematopoietic 1106 mel cells.
3.6. Aiolos expression is regulated by histone modiﬁcations in
primary cells
Fig. 8 shows that freshly isolated T and B cells show a high
enrichment in H3K4 di- and tri-methylated histones as well asin the acetylation of histone H3K9. There is a diﬀerence in the
tri-methylated H3K4 enrichment between the two types of
cells, which could explain the diﬀerent level of Aiolos expres-
sion. The tri-methylated H3K9 and H3K27 heterochromatin
markers are negatives in both cells. Monocytes, as well as mel-
anocytes show a signiﬁcant enrichment in histone markers of
heterochromatin, while the euchromatin markers are negative.
The histone modiﬁcations are detected preferentially down-
stream of the Aiolos promoter in monocytes while they are dis-
tributed upstream and downstream of the ATG in T and B
cells and melanocytes. These results show a signiﬁcant hetero-
chromatinization of Aiolos in monocytes and melanocytes and
suggest that Aiolos expression in primary cells is mainly
controlled by histone modiﬁcations rather than DNA
methylation.4. Discussion
Aiolos is an essential regulator of lymphoid diﬀerentiation
and homeostasis. However, nothing is known concerning the
molecular mechanism that control its expression. In this man-
uscript, we analyzed the contribution of epigenetic modiﬁca-
tions controlling silencing of Aiolos transcription in two
scenarios: cancer cell lines and primary cells. We have found
that DNA methylation is required to maintain Aiolos silencing
in tumor cell lines (U937 and 1106 mel), but not in freshly iso-
lated monocytes and melanocytes, where the silencing mecha-
nism relies on post-translational modiﬁcations of histone H3.
We have identiﬁed a CpG island located at the Aiolos pro-
moter, which exhibits diﬀerential methylation between Aiolos
expressing and non-expressing cell lines. This suggests that
DNA methylation of 5 0CpG island participates into the main-
tenance of Aiolos silencing in non-expressing cell lines. Treat-
ment with 5-Aza-dC of U937 and 1106 mel cells induced DNA
demethylation and Aiolos expression. In addition, withdrawal
of the demethylating agent in positive clones derived from the
treated cell lines did not re-induce Aiolos silencing, indicating
that demethylation of Aiolos 5 0CpG island induces its shift to
an active epigenetic state that favours long term expression.
Those results demonstrate that DNA methylation of the
CpG island is responsible for silencing Aiolos in tumoral cell
lines. Our results are compatible with the notion that Aiolos
expressing and non-expressing cells have the transcription fac-
tors necessary for Aiolos expression, independently of whether
or not they express the gene.
A correlation between gene silencing and CpG methylation
around the transcription start site has been reported for genes
on the inactive X chromosome [13] such as HPRT and PGK1,
that contain a CpG rich TATA less promoter. It has been sug-
gested that methylation of CpG island near the transcription
start site inhibits binding of the basal transcription machinery
on these genes and therefore repress their expression. This
mechanism has been observed in the regulation of E2F activity
[14]. This does not exclude that methylation of CpG sites lo-
cated further from the transcription initiation site might con-
tribute to the silencing of Aiolos [15]. We analyzed DNA
methylation patterns of the Aiolos 5 0CpG island in Aiolos
expressing and non-expressing freshly isolated cells. We did
not ﬁnd any signiﬁcant methylation of Aiolos promoter region
in none of the primary cells. This indicates that DNA methyl-
ation is not required to silence Aiolos in primary cells and sug-
Fig. 6. Chromatin immunoprecipitation of histone modiﬁcations in cell lines. (A) Schematic representation of the position of the primer pairs used to
analyze chromatin remodelling within Aiolos promoter. (B) Analysis of di- and tri-methylation H3K4 histone, H3K9 acetylation and H3K9 and
H3K27 tri-methylation in Daudi, Jurkat, U937 and 1106 mel cells. For each panel, the average percent of immunoprecipitation calculated for each
position is plotted against genomic localization with respect to Aiolos transcription initiation site. The Y-axis corresponds to the percentage of
immunoprecipitated chromatin. The X-axis corresponds to the position in the promoter of the chromatin modiﬁcation.
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Fig. 7. Chromatin immunoprecipitation of histone modiﬁcations in 5-Aza-dC-treated cells. Analysis of histone H3K4 di- and tri-methylation and
H3K9 acetylation in U937 and 1106 mel cells treated with 5-Aza-dC. Results were analyzed as above. NT; non-treated cells. The corresponding
methylated proﬁles are shown in Fig. 4. The Y-axis corresponds to the percentage of immunoprecipitated chromatin. The X-axis corresponds to the
position in the promoter of the chromatin modiﬁcation.
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required to control Aiolos expression. In the same direction,
absence of DNA methylation has been associated with trans-
criptionally inactive genes such as alpha-globin and collagen
[16,17].
In addition to DNA methylation of CpG islands, modiﬁca-
tion of the N-terminal tail of histones play crucial role in chro-
matin organization and function. Histones H3K4 (lysine 4)
and K27 (lysine 27) methylation are of particular interest sincelysine 4 methylation positively regulates transcription by
recruiting nucleosome remodelling enzymes and histone acety-
lases [18,19] while lysine 27 methylation negatively regulates
transcription by promoting a compact chromatin structure
[20].
We asked whether a particular set of histone modiﬁcation
marks the Aiolos 5 0 region in the cellular models used in this
study. In Aiolos expressing cells, either tumoral cell lines or
freshly isolated T and B cells, high level of the euchromatin-
Fig. 8. Chromatin immunoprecipitation of histone modiﬁcations in primary cells. (A) Schematic representation of the position of the primer
pairs used to analyze chromatin remodelling within Aiolos promoter. (B) Analysis of histone H3K4 di- and tri-methylation, H3K9 acetylation and
H3K9 and H3K27 tri-methylation in primary cells; T and B cells, monocytes and melanocytes. Results were analyzed as above. The Y-axis
corresponds to the percentage of immunoprecipitated chromatin. The X-axis corresponds to the position in the promoter of the chromatin
modiﬁcation.
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particular, Daudi, T and B cells, but not Jurkat cells displayed
high level of the three tested marks. The pattern of euchroma-
tin marks was perfectly correlated with that of heterochroma-
tin marks. This clearly shows that Aiolos expressing cells
display a fully euchromatic structure around Aiolos 5 0 region.
Interestingly, in Jurkat cells, where only H3K4 di-methylation
marks the promoter region, consistent level of the H3K27 tri-
methylated mark were detected. Studies in primary ﬁbroblast
revealed several genomic sites associated with lysine 4 methyl-
ation, however little is known about the genomic distribution
of repressive marker lysine 27 methylation [21,22]. This novel
chromatin modiﬁcation pattern named bivalent chromatin,
consists of large regions of lysine 27 methylation harbouring
smaller regions of Lys 4 methylation. These regions thus har-
bour both repressive and activating chromatin modiﬁcations.
We do not know whether the observed bivalent domain in Jur-
kat cells reﬂects the simultaneous presence of both Lys 4 and
Lys 27 methylation or perhaps two subpopulations with dis-
tinct characteristics, or one population alternating between
two states. It has been previously described that bivalent do-
mains are associated with low levels of gene expression [23],
which is consistent with Aiolos expression observed in Jurkat
cells, that express lower level of Aiolos than Daudi cells. It
has also been suggested that bivalent chromatin is characteris-
tic of pluripotent cells, silencing developmental genes while
keeping then poised for induction upon initiation of speciﬁc
developmental pathways.
More importantly, in Aiolos non-expressing cell, we found
no enrichment for the euchromatin marks neither in U937
and 1106 mel nor in monocytes and melanocytes. This result
conﬁrm the relationship between gene silencing and absence
of euchromatin marks over the promoter. The lack of euchro-
matin marks was accompanied by the enrichment in hetero-
chromatin marks in 1106 mel cell line but not in U937. This
indicates that DNA methylation and not histone modiﬁcations
is the common mechanism to induce lost of transcriptional
activity of the Aiolos promoter in tumoral cell lines. In con-
trast, in Aiolos non-expressing primary cells, where the meth-
ylation of the Aiolos CpG island is absent, both H3K9 and
H3K27 tri-methylated were highly enriched. This highlights
methylation of H3K9 and H3K27 as a fundamental mecha-
nism of Aiolos repression in primary cells without requirement
of DNA methylation.
The recover of Aiolos expression in U937 and 1106 mel cell
lines upon 5-Aza-dC treatment, as well as the euchromatin-
associated signature, suggests a connection between DNA
methylation and histones modiﬁcation. DNA methylation
silences expression of multiple tumor suppressor genes by
inducing repressive chromatin structures mediated by binding
of methyl-CpG binding proteins to methylated DNA, all asso-
ciated with histone deacetylase activity and chromatin remod-
eling factors.
Treatment of the cells with inhibitors of histone deacetylases
results in accumulation of hyperacetylated histones and activa-
tion of repressed genes. Interesting, some methylated promot-
ers, e.g. MLH1, TIMP3, INKN2A, INKN2B, ER and MDR1
can be activated with TSA after partial demethylation with
5-Aza-dC [24]. It has been reported that TSA treatment can
aﬀect DNA methylation state [25]. Another potential mecha-
nism by which TSA plus 5-Aza-dC function synergistically
may be through the activation of a key transcription factorthat regulates Aiolos expression. Alternatively, TSA treatment
may alter post-transcriptional modiﬁcations, facilitating in-
creased association with the Aiolos promoter. This result indi-
cates that in 1106 mel cells stable repression of Aiolos
promoter is mainly mediated by histone deacetylation-
dependent mechanism. Similar results have been obtained with
cyclin A1 in HeLa cells. It has been recently shown that his-
tone modiﬁcation, as well as DNA methylation, are important
elements in the modulation of Ikaros gene expression in pitu-
itary tumour cells [10].
Our results suggest that fundamentally diﬀerent mechanisms
trigger Aiolos repression in tumor cell lines and hematopoietic
primary cells. In the ﬁrst case, DNA methylation seems to be
an important epigenetic modiﬁcation controlling Aiolos
expression and chromatin modiﬁcations while in hematopoi-
etic primary cells, histone modiﬁcations are the main epige-
netic modiﬁcation involved in the control of Aiolos
expression. Taken together, our data highlight the critical role
of epigenetic mechanisms, as a part of Aiolos silencing.
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